Cue Biopharma Yönetim

Yönetim kriter kontrolleri 2/4

Cue Biopharma CEO'su Dan Passeri, Aug2016 tarihinde atandı, in görev süresi 8.25 yıldır. in toplam yıllık tazminatı $ 3.02M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.1% maaş ve 79.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.21% ine doğrudan sahiptir ve bu hisseler € 136.16K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.5 yıl ve 6.3 yıldır.

Anahtar bilgiler

Dan Passeri

İcra Kurulu Başkanı

US$3.0m

Toplam tazminat

CEO maaş yüzdesi	20.1%
CEO görev süresi	8.3yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	6.5yrs
Yönetim Kurulu ortalama görev süresi	6.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Dan Passeri'un ücretlendirmesi Cue Biopharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$45m
Jun 30 2024	n/a	n/a	-US$47m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$3m	US$605k	-US$51m
Sep 30 2023	n/a	n/a	-US$52m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$1m	US$748k	-US$53m
Sep 30 2022	n/a	n/a	-US$47m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$46m
Dec 31 2021	US$2m	US$531k	-US$44m
Sep 30 2021	n/a	n/a	-US$47m
Jun 30 2021	n/a	n/a	-US$44m
Mar 31 2021	n/a	n/a	-US$44m
Dec 31 2020	US$6m	US$501k	-US$45m
Sep 30 2020	n/a	n/a	-US$43m
Jun 30 2020	n/a	n/a	-US$40m
Mar 31 2020	n/a	n/a	-US$38m
Dec 31 2019	US$1m	US$395k	-US$37m
Sep 30 2019	n/a	n/a	-US$39m
Jun 30 2019	n/a	n/a	-US$45m
Mar 31 2019	n/a	n/a	-US$43m
Dec 31 2018	US$834k	US$345k	-US$39m
Sep 30 2018	n/a	n/a	-US$38m
Jun 30 2018	n/a	n/a	-US$30m
Mar 31 2018	n/a	n/a	-US$27m
Dec 31 2017	US$410k	US$325k	-US$23m

Tazminat ve Piyasa: Dan 'nin toplam tazminatı ($USD 3.02M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 472.15K ).

Tazminat ve Kazançlar: Dan şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Dan Passeri (63 yo)

8.3yrs

Görev süresi

US$3,015,480

Tazminat

Mr. Daniel R. Passeri, also known as Dan, MSc. J.D. has been the Chief Executive Officer and Director of Cue Biopharma, Inc. since August 2016 and also served as its President since August 2016 until Octob...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Passeri	CEO & Director	8.3yrs	US$3.02m	0.21% € 136.2k
Kerri-Ann Millar	Chief Financial Officer	6.5yrs	US$1.16m	0.023% € 14.5k
Ronald Seidel	Co-Founder	no data	US$316.63k	Veri yok
Rodolfo Chaparro	Co-Founder & Senior Advisor	no data	US$316.63k	Veri yok
Steven Almo	Co-Founder and Chairman of Scientific & Clinical Advisory Board	no data	Veri yok	Veri yok
Colin Sandercock	Senior VP	6.9yrs	US$625.51k	Veri yok
Matteo Levisetti	Chief Medical Officer	3.8yrs	Veri yok	Veri yok
Lucinda Warren	Chief Business Officer	less than a year	Veri yok	Veri yok

6.5yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 1UC 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Passeri	CEO & Director	8.3yrs	US$3.02m	0.21% € 136.2k
Steven Almo	Co-Founder and Chairman of Scientific & Clinical Advisory Board	9.8yrs	Veri yok	Veri yok
Frederick Driscoll	Independent Director	6.4yrs	US$76.31k	0% € 0
Frank Morich	Independent Chairman of the Board	6.3yrs	US$106.27k	0.044% € 28.3k
Peter Kiener	Independent Director	8.7yrs	US$144.18k	0.00056% € 358.9
Hidde L. Ploegh	Member of Scientific & Clinical Advisory Board	no data	Veri yok	Veri yok
Rafi Ahmed	Member of Scientific Advisory Board	1.8yrs	Veri yok	Veri yok
Kenneth Pienta	Clinical Advisor	1.8yrs	Veri yok	Veri yok
Patrick Verheyen	Independent Director	1.6yrs	US$135.31k	0.013% € 8.3k
Abul K. Abbas	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Karolina Palucka	Member of Scientific & Clinical Advisory Board	7.8yrs	Veri yok	Veri yok
Michael Kalos	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok

6.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1UC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).

Cue Biopharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Business Officer

Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee

Cue Biopharma, Inc., Annual General Meeting, Jun 05, 2024

Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023

Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board

Recent updates

Third quarter 2024 earnings released: US$0.17 loss per share (vs US$0.24 loss in 3Q 2023)

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma, Inc. Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Business Officer

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Financial position

Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.29 loss in 2Q 2023)

Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell Small Cap Completeness Index

Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee

First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.29 loss in 1Q 2023)

First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.29 loss in 1Q 2023)

Cue Biopharma, Inc., Annual General Meeting, Jun 05, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.11 loss per share (vs US$1.49 loss in FY 2022)

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.31 loss in 3Q 2022)

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

New minor risk - Market cap size

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?

Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.29 loss per share (vs US$0.37 loss in 2Q 2022)

Cue Biopharma, Inc. Presents Positive Data Update from Ongoing Phase 1 Trials of Cue-101 for Recurrent/Metastatichpv+ Head and Neck Squamous Cell Carcinoma At the 2023 American Society of Clinical Oncology Annual Meeting

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $17.6 million.

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.44 loss in 1Q 2022)

Full year 2022 earnings released: US$1.49 loss per share (vs US$1.41 loss in FY 2021)

Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board

Cue Biopharma, Inc. Announces Executive Changes

Cue Biopharma, Inc. announced that it expects to receive $29.999992 million in funding

Cue Biopharma, Inc. Presents New Positive Data from Ongoing Phase 1 Trial of Cue-101 in Combination with Keytruda for Recurrent/Metastatic Hpv+ Head and Neck Cancer At the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Cue Biopharma Grants FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - Expressing Cancers

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.33 loss in 2Q 2021)

Cue Biopharma, Inc. Announces Resignation of Cameron Gray as Member of the Board of Directors and All Committees

Insider recently bought €98k worth of stock

U.S. Food and Drug Administration Accepts Cue Biopharma, Inc Investigational New Drug Application

First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.41 loss in 1Q 2021)

Cue Biopharma, Inc., Annual General Meeting, Jun 09, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.34 loss in 3Q 2020)

Cue Biopharma, Inc. Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

Cue Biopharma, Inc Grants U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.38 loss in 2Q 2020)

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

Cue Biopharma to Present A Corporate and Clinical Progress Update At the Upcoming Jefferies Virtual Healthcare Conference

First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.48 loss in 1Q 2020)

Cue Biopharma Reports Confirms Partial Response in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

Cue Biopharma, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2020

Revenue misses expectations

Full year 2020 earnings released: US$1.56 loss per share (vs US$1.67 loss in FY 2019)

Cue Biopharma, Inc. Announces Executive Changes

Cue Biopharma, Inc. Appoints Dr. Matteo Levisetti as Senior Vice President of Clinical Development, Effective February 22, 2021

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA

New 90-day low: €9.95

Independent Director recently bought €70k worth of stock

Cue Biopharma, Inc. Extends Research Collaboration for the Development of Immuno-Stat Biologics for the Treatment of Defined Autoimmune Diseases with Merck

New 90-day low: €10.80

Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting

Independent Director recently bought €129k worth of stock

New 90-day low: €12.80

Cue Biopharma, Inc. Announces Appointment of Tamar Howson to Board of Directors

New 90-day low - €15.50

First half earnings released

New 90-day low - €17.90

CEO Tazminat Analizi